Prevalence of probable invasive pulmonary Aspergillosis in Ahvaz, southwest Iran during the third and fourth wave of the COVID-19 pandemic by using serum Galactomannan antigen test
نویسندگان: Neda Kiasat ©, Ameneh Takesh, Faleh Darvishi, Mahnaz Fatahinia, Ali Zarei Mahmoudabadi , Marziye Esmaeilpour Jouneghani, Maryam Erfaninejad, Shahla Ahmadi Halili, Sasan Moogahi, Mehdi Ahmadi, Ali Amin Asnafi
زمان بندی نشده!
قارچ شناسی پزشکی
دانلود: دانلود پوستر
Background and Aim
Nowadays, the pandemic of coronavirus (COVID-19) is a major health problem that takes over entire the world. Fungal infections, especially invasive Aspergillosis as a co-infection have increased considerably during the outbreak of COVID-19 disease. Invasive pulmonary Aspergillosis (IPA) is a fatal fungal disease caused by the invasion of Aspergillus species to the host’s tissue. The aim of this study was to evaluate probable IPA in patients with complicated acute respiratory distress syndrome (ARDS).
From Nev. 2020 to the Sep. 2021, a number of 157 patients (87.9% from 6 hospitals and 12.1% of patients were outpatients) were evaluated and followed for probable IPA in Ahwaz. Probable IPA was determined based on clinical findings, chest CT and positive serum galactomannan (GM) antigen results. All of the collected serum samples were assayed for GM antigen using the Dynamiker Aspergillus Galactomannan enzyme-linked immunosorbent assay (ELISA) kite. GM index cutoff ≥0.5 is considered to be positive for GM antigen.
Overall, GM antigen was assayed in 157 patients. From 103 (65.6%) patients, 31(56.36%) and 72 (70.58%) cases respectively in the third and fourth wave of COVID-19 pandemic infected with COVID-19 and other patients were not infected by the COVID-19. From the total of 55 samples collected during the third wave of the COVID-19, which the GM antigen test was positive in 12 samples (21.84%) and negative in 43 samples (78.16%) as well as from 102 samples collected during the fourth wave, that was positive in 56 samples (54.92%) and negative in 44 samples (40.8%).
Due to the higher prevalence of probable IPA in the fourth wave of the COVID-19 compared to the third wave, it can be concluded that COVID-19 infection is a major risk factor for IPA. Furthermore, clinical weekly screening of serum GM strongly recommended to perform in COVID-19 patients.
Coronavirus (COVID-19); Enzyme-linked immunosorbent assay (ELISA); invasive pulmonary Aspergillosis; Serum Galactomannan antigen
ارسال یک دیدگاه
ارسال دیدگاه توسط مدیریت بسته شده است.